SCHEMBL3097143

SCHEMBL3097143

N#Cc1cccc(CC(C(=O)O)C(=O)NS(=O)(=O)c2ccc3ccccc3c2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 3/20 0.54
PIN1 Q13526 1/20 0.52
CNR1 P21554 1/20 0.48
CNR2 P34972 1/20 0.48
LARS1 Q9P2J5 1/20 0.48
ADAMTS4 O75173 1/20 0.46
MMP13 P45452 1/20 0.46
LMNA P02545 1/20 0.45
CYP19A1 P11511 1/20 0.44
F2 P00734 1/20 0.44
FOLH1 Q04609 1/20 0.44
CTSS P25774 1/20 0.43
SLC1A3 P43003 1/20 0.43
SLC1A2 P43004 1/20 0.43
SLC1A1 P43005 1/20 0.43
PLAT P00750 1/20 0.42
ALDH1A1 P00352 1/20 0.41
NLRP3 Q96P20 1/20 0.41
GPR34 Q9UPC5 1/20 0.41
SLC16A3 O15427 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3089218 0.89 KAT6A (0.51) KAT6ACNR1CNR2LARS1LMNA
SCHEMBL3090840 0.86 LARS1 (0.58) KAT6ALARS1LMNACYP19A1F2
SCHEMBL3090045 0.85 LARS1 (0.57) KAT6ALARS1MMP13LMNACYP19A1
SCHEMBL7566084 0.85 MMP2 (0.58) KAT6APIN1CNR1CNR2ADAMTS4
SCHEMBL18049375 0.85 MMP2 (0.58) KAT6APIN1CNR1CNR2ADAMTS4
SCHEMBL3092119 0.84 KAT6A (0.51) KAT6ALARS1ADAMTS4MMP13LMNA
SCHEMBL3092646 0.82 KAT6A (0.46) KAT6APIN1CNR1CNR2LARS1
SCHEMBL9665279 0.81 PLAT (0.58) KAT6APIN1CNR1CNR2CYP19A1
SCHEMBL3103948 0.80 KAT6A (0.55) KAT6ALARS1ADAMTS4MMP13LMNA
SCHEMBL3091186 0.79 LARS1 (0.53) KAT6ACNR1CNR2LARS1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 KAT6A 3337/4885PIN1 2537/4885CNR1 1167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.